Tumour suppressive mechanisms of CEBP? and PU.1 in acute myeloid leukemia

CEBP的抑癌机制？

• 批准号: nhmrc : 1057854
• 负责人: A/Pr Ross Dickins
• 金额: $ 33.2万
• 依托单位: Monash University
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2014
• 资助国家: 澳大利亚
• 起止时间: 2014-01-01 至 2016-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/tumour-suppressive-mechanisms-myeloid-leukemia/454639
• 关键词: Tumour; suppressive; mechanisms; CEBP; PU.1

Acute myeloid leukaemia (AML) is an aggressive leukaemia with poor overall responses to therapy. The transcription factors CEBPA and PU.1 are often lost during AML development, and therapies that can restore their normal functions hold great promise. By identifying the genes that these transcription factors regulate in normal and leukaemic white blood cells, this project aims to understand how AML develops and which genes represent rational drug targets for this disease.

急性髓性白血病（AML）是一种侵袭性白血病，对治疗的总体反应较差。转录因子CEBPA和PU.1通常在AML发展过程中丢失，可以恢复其正常功能的疗法具有很大的希望。通过鉴定这些转录因子在正常和白血病白色血细胞中调节的基因，该项目旨在了解AML如何发展以及哪些基因代表这种疾病的合理药物靶点。